The estimated Net Worth of Hangjun Zhan is at least $426 millier dollars as of 22 January 2021. Hangjun Zhan owns over 6,250 units of Kindred Biosciences Inc stock worth over $426,203 and over the last 7 years Hangjun sold KIN stock worth over $0.
Hangjun has made over 3 trades of the Kindred Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Hangjun exercised 6,250 units of KIN stock worth $57,813 on 22 January 2021.
The largest trade Hangjun's ever made was exercising 6,250 units of Kindred Biosciences Inc stock on 22 January 2021 worth over $57,813. On average, Hangjun trades about 2,344 units every 46 days since 2018. As of 22 January 2021 Hangjun still owns at least 46,076 units of Kindred Biosciences Inc stock.
You can see the complete history of Hangjun Zhan stock trades at the bottom of the page.
Hangjun's mailing address filed with the SEC is C/O KINDRED BIOSCIENCES, INC., 1555 BAYSHORE HIGHWAY, SUITE 200, BURLINGAME, CA, 94010.
Over the last 11 years, insiders at Kindred Biosciences Inc have traded over $10,542,886 worth of Kindred Biosciences Inc stock and bought 50,952,388 units worth $461,948,778 . The most active insiders traders include Animal Health Inc Elanco, West Asset Management Llc Park et Ernest Mario. On average, Kindred Biosciences Inc executives and independent directors trade stock every 34 days with the average trade being worth of $5,949,674. The most recent stock trade was executed by Animal Health Inc Elanco on 27 August 2021, trading 45,508,938 units of KIN stock currently worth $420,957,677.
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
Kindred Biosciences Inc executives and other stock owners filed with the SEC include: